Show simple item record

dc.contributor.authorTaylor, AEen_US
dc.contributor.authorMartin, RMen_US
dc.contributor.authorGeybels, MSen_US
dc.contributor.authorStanford, JLen_US
dc.contributor.authorShui, Ien_US
dc.contributor.authorEeles, Ren_US
dc.contributor.authorEaston, Den_US
dc.contributor.authorKote-Jarai, Zen_US
dc.contributor.authorAmin Al Olama, Aen_US
dc.contributor.authorBenlloch, Sen_US
dc.contributor.authorMuir, Ken_US
dc.contributor.authorGiles, GGen_US
dc.contributor.authorWiklund, Fen_US
dc.contributor.authorGronberg, Hen_US
dc.contributor.authorHaiman, CAen_US
dc.contributor.authorSchleutker, Jen_US
dc.contributor.authorNordestgaard, BGen_US
dc.contributor.authorTravis, RCen_US
dc.contributor.authorNeal, Den_US
dc.contributor.authorPashayan, Nen_US
dc.contributor.authorKhaw, K-Ten_US
dc.contributor.authorBlot, Wen_US
dc.contributor.authorThibodeau, Sen_US
dc.contributor.authorMaier, Cen_US
dc.contributor.authorKibel, ASen_US
dc.contributor.authorCybulski, Cen_US
dc.contributor.authorCannon-Albright, Len_US
dc.contributor.authorBrenner, Hen_US
dc.contributor.authorPark, Jen_US
dc.contributor.authorKaneva, Ren_US
dc.contributor.authorBatra, Jen_US
dc.contributor.authorTeixeira, MRen_US
dc.contributor.authorPandha, Hen_US
dc.contributor.authorPRACTICAL Consortiumen_US
dc.contributor.authorDonovan, Jen_US
dc.contributor.authorMunafò, MRen_US
dc.date.accessioned2017-01-30T13:58:38Z
dc.date.issued2017-01en_US
dc.identifier.citationInternational journal of cancer, 2017, 140 (2), pp. 322 - 328en_US
dc.identifier.issn0020-7136en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/395
dc.identifier.eissn1097-0215en_US
dc.identifier.doi10.1002/ijc.30462en_US
dc.description.abstractCoffee consumption has been shown in some studies to be associated with lower risk of prostate cancer. However, it is unclear if this association is causal or due to confounding or reverse causality. We conducted a Mendelian randomisation analysis to investigate the causal effects of coffee consumption on prostate cancer risk and progression. We used two genetic variants robustly associated with caffeine intake (rs4410790 and rs2472297) as proxies for coffee consumption in a sample of 46,687 men of European ancestry from 25 studies in the PRACTICAL consortium. Associations between genetic variants and prostate cancer case status, stage and grade were assessed by logistic regression and with all-cause and prostate cancer-specific mortality using Cox proportional hazards regression. There was no clear evidence that a genetic risk score combining rs4410790 and rs2472297 was associated with prostate cancer risk (OR per additional coffee increasing allele: 1.01, 95% CI: 0.98,1.03) or having high-grade compared to low-grade disease (OR: 1.01, 95% CI: 0.97,1.04). There was some evidence that the genetic risk score was associated with higher odds of having nonlocalised compared to localised stage disease (OR: 1.03, 95% CI: 1.01, 1.06). Amongst men with prostate cancer, there was no clear association between the genetic risk score and all-cause mortality (HR: 1.00, 95% CI: 0.97,1.04) or prostate cancer-specific mortality (HR: 1.03, 95% CI: 0.98,1.08). These results, which should have less bias from confounding than observational estimates, are not consistent with a substantial effect of coffee consumption on reducing prostate cancer incidence or progression.en_US
dc.formatPrint-Electronicen_US
dc.format.extent322 - 328en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectPRACTICAL Consortiumen_US
dc.subjectHumansen_US
dc.subjectProstatic Neoplasmsen_US
dc.subjectDisease Progressionen_US
dc.subjectRisk Factorsen_US
dc.subjectAllelesen_US
dc.subjectCoffeeen_US
dc.subjectAgeden_US
dc.subjectMiddle Ageden_US
dc.subjectMaleen_US
dc.subjectGenetic Variationen_US
dc.subjectMendelian Randomization Analysisen_US
dc.titleInvestigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-09-05en_US
rioxxterms.versionofrecord10.1002/ijc.30462en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en_US
rioxxterms.licenseref.startdate2017-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfInternational journal of canceren_US
pubs.issue2en_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume140en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamOncogeneticsen_US
dc.contributor.icrauthorEeles, Rosalinden_US
dc.contributor.icrauthorKote-Jarai, Zsofiaen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record